About Our Company
We are focused on the development of serum based biomarker assays for Multiple Sclerosis. Multiple sclerosis (MS) is the most common disabling neurological condition of young adults, with over 2.5 million patients globally. Treatments are most effective at the early stage of disease, but MS is typically not diagnosed until several years after disease initiation. The current diagnostic biomarker is elevated IgG and oligoclonal bands in the cerebrospinal fluid, but these assays require painful lumbar puncture, are subjective, complex, not reliable for early disease diagnosis or prognosis, and cannot monitor treatment response. There is a great unmet medical need for objective biomarkers for MS patient care. We are focused on developing non-invasive, quantifiable, and simple serum-based MS diagnostic assays.
We are currently testing the feasibility of several biomarkers for MS diagnosis. We have built a strong team consisting of PhD scientists, MS clinicians, statistician and expert in diagnostic assay development to ensure success of the development. We have lab and office space at the Fitzsimons Innovation Campus, with access to all research supplies and equipment.
The goal of next 3 years is to continue validation of the different components of the assays; assessment of patient samples for diagnosis, prognosis and response to therapy; increase sample size to increase significance; standardize the assay, refine and optimize commercial kits, and finally conduct a large preclinical evaluation.
